Bafna Pharmaceuticals Reports Strong Annual Profit Growth Amid Tax Litigation

Bafna Pharmaceuticals has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a net profit of ₹11.10 crore for the full fiscal year, a substantial increase from ₹4.15 crore in the previous year.

Reader Takeaway: Annual profit surges, but ₹5.66 crore tax litigation poses a key risk.

What just happened

Bafna Pharmaceuticals announced its audited financial results for the fiscal year ended March 31, 2026 (FY26). The company reported a net profit of ₹11.10 crore for FY26, a significant jump from ₹4.15 crore in FY25. For the fourth quarter of FY26, net profit stood at ₹2.75 crore, down from ₹3.11 crore in the same quarter last year. The Board of Directors approved these results on May 29, 2026, with the statutory auditor issuing an unmodified audit opinion.

Why this matters

The strong annual profit growth suggests improved operational performance and profitability for Bafna Pharmaceuticals. The unmodified audit opinion provides assurance regarding the company's financial reporting. However, ongoing tax litigation presents a potential financial overhang.

The backstory

In FY26, Bafna Pharmaceuticals saw its revenue from operations grow to ₹150.62 crore, up from ₹145.86 crore in FY25. The company's profit for the period also saw a substantial increase year-on-year. In the fourth quarter, revenue from operations was ₹42.24 crore, compared to ₹39.06 crore in the prior year's fourth quarter.

What changes now

Investors can note the positive annual financial performance, particularly the substantial increase in net profit. The company has appealed against GST demand and refund recovery orders totaling ₹5.66 crore (₹2.35 crore demand plus ₹3.31 crore refund recovery), with a stay obtained on the refund recovery. Management expressed confidence in resolving these matters favorably.

Risks to watch

The primary risk for investors is the ongoing tax litigation involving GST authorities. The company is contesting demands and recovery orders amounting to approximately ₹5.66 crore. Adverse outcomes in these legal proceedings could impact the company's financial health.

Peer comparison

While specific peer data is not provided in the filing, the company's annual profit growth will be a key metric for comparison against other pharmaceutical companies in its segment. Investors should assess how Bafna's profitability trends align with industry averages.

Context metrics (time-bound)

• FY26 Revenue: ₹150.62 crore (vs. ₹145.86 crore in FY25)
• FY26 Net Profit: ₹11.10 crore (vs. ₹4.15 crore in FY25)
• Q4 FY26 Net Profit: ₹2.75 crore (vs. ₹3.11 crore in Q4 FY25)
• GST Litigation: ₹5.66 crore

What to track next

Investors should closely monitor the progress and outcome of the GST litigation. Additionally, tracking the company's revenue and profit trajectory in upcoming quarters will be crucial to assess sustained growth.